Drug
D0083 | Mitomycin
L
L01DC03 Mitomycin
[L01DC] Other cytotoxic antibiotics
[L01D] CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
[L01] ANTINEOPLASTIC AGENTS
[L] Antineoplastic and immunomodulating agents
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | > 200 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | EC20 | 36 |
| RESPIRATION | 4.9 µM | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. | decrease | EC20 | 36 |
| RESPIRATION | ND | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. | Negative | EC20 | 36 |
| SWELLING | ND | 30 mins | mouse | liver mitochondria | swelling assay: Absorbance at 545 nm using a fluorescence multi-well plate reader (CaCl2 (50 µM) was considered as the 100% baseline for the swelling ) | Negative | EC20 | 36 |
| Target | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| NADH:ubiquinone reductase | 4.9 µM | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. | inhibit | EC20 | 36 |
| Succinate dehydrogenase | ND | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. | Negative | EC20 | 36 |
| Cytochrome c | > 200 µM | 30 mins | mouse | liver mitochondria | Cytochrome c release was evaluated using ELISA kit ( 20 µg/ml Alamethicin was used as 100% baseline) | release | EC20 | 36 |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
  |
Danger |
Aggregated GHS information provided by 53 companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H300 (92.45%): Fatal if swallowed [Danger Acute toxicity, oral] H351 (92.45%): Suspected of causing cancer [Warning Carcinogenicity] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P201, P202, P264, P270, P281, P301+P310, P308+P313, P321, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| rabbit | LD50 | intravenous | 3400ug/kg (3.4mg/kg) | Drugs in Japan Vol. -, Pg. 1129, 1990. | |
| quail | LD50 | oral | > 100mg/kg (100mg/kg) | Ecotoxicology and Environmental Safety. Vol. 6, Pg. 149, 1982. | |
| mouse | LDLo | intratracheal | 4mg/kg (4mg/kg) | Toxicology Letters. Vol. 30, Pg. 63, 1986. | |
| mouse | LD50 | unreported | 12mg/kg (12mg/kg) | Cancer Research. Vol. 46, Pg. 2703, 1986. | |
| rat | LD50 | intraperitoneal | 2mg/kg (2mg/kg) | Advances in Teratology. Vol. 3, Pg. 181, 1968. | |
| mouse | LD50 | intraperitoneal | 4mg/kg (4mg/kg) | Journal of Antibiotics, Series A. Vol. 13, Pg. 27, 1960. | |
| monkey | LDLo | intravenous | 1mg/kg (1mg/kg) | Cancer Research. Vol. 20, Pg. 1354, 1960. | |
| man | TDLo | unreported | 1350ug/kg/21W (1.35mg/kg) | Archives of Internal Medicine. Vol. 143, Pg. 803, 1983. | |
| women | TDLo | unreported | 2100ug/kg/40W (2.1mg/kg) | Archives of Internal Medicine. Vol. 143, Pg. 1617, 1983. | |
| mouse | LD50 | subcutaneous | 7300ug/kg (7.3mg/kg) | Japanese Journal of Cancer Research. Vol. 80, Pg. 670, 1989. | |
| women | TDLo | intravenous | 1800ug/kg (1.8mg/kg) | Lancet. Vol. 2, Pg. 1037, 1980. | |
| rat | LD50 | subcutaneous | 3250ug/kg (3.25mg/kg) | Drugs in Japan Vol. 6, Pg. 798, 1982. | |
| dog | LD50 | intravenous | 720ug/kg (0.72mg/kg) | Drugs in Japan Vol. -, Pg. 1129, 1990. | |
| rat | LD50 | oral | 30mg/kg (30mg/kg) | Cancer Research. Vol. 20, Pg. 1354, 1960. | |
| cat | LDLo | intravenous | 2500ug/kg (2.5mg/kg) | Cancer Research. Vol. 20, Pg. 1354, 1960. | |
| bird - wild | LD50 | oral | 7500ug/kg (7.5mg/kg) | Archives of Environmental Contamination and Toxicology. Vol. 12, Pg. 355, 1983. | |
| rat | LD50 | intravenous | 3mg/kg (3mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1467, 1970. | |
| mouse | LD50 | oral | 23mg/kg (23mg/kg) | Cancer Research. Vol. 20, Pg. 1354, 1960. | |
| mouse | LD50 | intravenous | 4mg/kg (4mg/kg) | Journal of Antibiotics, Series A. Vol. 13, Pg. 27, 1960. | |
| ((1aS,8S,8aR,8bS)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2',3':3,4]pyrrolo[1,2-a]indol-8-yl)methyl carbamate | (1ar)-6-amino-8-(((aminoc arbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione | (1ar)-6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione |
| (amino-methoxy-methyl-dioxo-[?]yl)methyl carbamate | 078M109 | 1404-00-8 |
| 50-07-7 | 50SG953SK6 | 6-Amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methylazirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione carbamate (ester) |
| 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methylazirino[2',3':3, 4]pyrrolo[1,2-a]indole-4,7-dione, carbamate (ester) | 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, carbamate (ester) | 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl, [1aS-(1aalpha,8beta,8aalpha,8balpha)]-azirino[2',3':3,4]pyrrol o[1,2a]indole-4,7-dione |
| 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl, [1aS-(1aalpha,8beta,8aalpha,8balpha)]-azirino[2',3':3,4]pyrrolo[1,2a]indole-4,7-dione | 7-Amino-9.alpha.-methoxymitosane | 7-Amino-9alpha-methoxymitosane |
| AB00918689-03 | AB00918689-04 | ACN-038344 |
| AI3-26199 | AKOS015895703 | AMETYCIN pound notmitomycin C |
| Ametycin | Ametycine | Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methyl-, carbamate (ester) |
| Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS,8S,8aR,8bS)- | Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS-(1aalpha,8beta,8aalpha,8balpha))- | Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS-(1aalpha,8beta,8aalpha,8balpha))- (9CI) |
| Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl -, [1aS-(1aalpha,8beta,8aalpha,8balpha)]- | Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS,8S,8aR,8bS)- | Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, [1aS-(1aalpha,8beta,8aalpha,8balpha)]- |
| Azirino[2',4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a- methoxy-5-methyl-, carbamate (ester) | Azirino[2',4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b- hexahydro-8a-methoxy-5-methyl-, [1aR-(1a.alpha.,8.beta.,8a.alpha.,8b.alpha.)]- | BCP0726000181 |
| BCP9000285 | BCPP000410 | BDBM50428658 |
| BRD-K59670716-001-02-6 | BRD-K59670716-001-06-7 | BSPBio_001267 |
| Bio1_000213 | Bio1_000702 | Bio1_001191 |
| Bio2_000464 | Bio2_000944 | C-20147 |
| C06681 | C15H18N4O5 | CAS-50-07-7 |
| CBiol_001927 | CC-30970 | CCG-208564 |
| CCRIS 414 | CHEBI:27504 | CHEMBL105 |
| CS-0564 | D00208 | DB00305 |
| DSSTox_CID_898 | DSSTox_GSID_20898 | DSSTox_RID_75853 |
| DTXSID2020898 | EINECS 200-008-6 | EX-A501 |
| GR-311 | GTPL7089 | HMS1362O09 |
| HMS1792O09 | HMS1990O09 | HMS2089F16 |
| HMS3403O09 | HSDB 3239 | HY-13316 |
| IDI1_002219 | KBio2_000607 | KBio2_003175 |
| KBio2_005743 | KBio3_001073 | KBio3_001074 |
| KBioGR_000607 | KBioSS_000607 | KS-5148 |
| LS-136 | LS-173087 | M2320 |
| MFCD00078109 | MLS001332654 | MLS002702984 |
| MMC | Mit-C | Mitamycin |
| Mito-C | MitoExtra | Mitocin C |
| Mitocin-C | Mitomicina | Mitomicina [INN-Spanish] |
| Mitomycin | Mitomycin (TN) | Mitomycin (USP/INN) |
| Mitomycin C (JP17) | Mitomycin C from Streptomyces caespitosus | Mitomycin C from Streptomyces caespitosus, >=970 mug/mg (USP XXIV) |
| Mitomycin C from Streptomyces caespitosus, >=98% (HPLC), potency: >=970 mug per mg (USP XXIV), gamma-irradiated, suitable for cell culture | Mitomycin C from Streptomyces caespitosus, powder, BioReagent, suitable for cell culture | Mitomycin C from Streptomyces caespitosus, powder, contains NaCl as solubilizer |
| Mitomycin C, Antibiotic for Culture Media Use Only | Mitomycin C, Streptomyces caespitosus | Mitomycin C, Streptomyces caespitosus, Carrier-Free |
| Mitomycin C, contains 2 mg Mitomycin C and 48 mg NaCl | Mitomycin [USAN:INN:BAN] | Mitomycin [USAN:USP:INN:BAN] |
| Mitomycin-C | Mitomycine | Mitomycine [INN-French] |
| Mitomycins | Mitomycinum | Mitomycinum C |
| Mitomycinum [INN-Latin] | Mitomycyna C | Mitomycyna C [Polish] |
| Mitonco | Mitoplus | Mitosol |
| Mitozytrex | Mitozytrex (TN) (Supergene) | Muamycin (TN) |
| Mutamycin | Mytomycin | Mytozytrex |
| NCGC00095258-01 | NCGC00163468-02 | NCGC00163468-03 |
| NCGC00163468-05 | NCGC00163468-06 | NCI-C04706 |
| NSC 26980 | NSC-26980 | NSC26980 |
| NWIBSHFKIJFRCO-WUDYKRTCSA-N | Q-201410 | Q19856779 |
| RCRA waste no. U010 | RCRA waste number U010 | SC-17000 |
| SCHEMBL3760 | SMP1_000307 | SMR000058401 |
| Tox21_111493 | Tox21_111493_1 | UNII-50SG953SK6 |
| UNII-V03E10691T component NWIBSHFKIJFRCO-WUDYKRTCSA-N | W-5071 | WLN: T D3 B556 BN EM JV MVTTT&J GO1 H1OVZ KZ L1 |
| ZINC30726187 | ZX-AFC000411 | [(1aS,8S,8aR,8bS)-6-Amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2'',3'':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate |
| [(1aS,8S,8aR,8bS)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate | [(1aS,8S,8aR,8bS)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate | [(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.0^{2,7}.0^{4,6}]trideca-1(9),11-dien-8-yl]methyl carbamate |
| [1aR-(1aalpha,8beta,8aalpha,8balpha)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-alpha]indole-4,7-dione | [1aS-(1a?,8?,8a?,8b?)]-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione | [1aS-(1aalpha,8beta,8aalpha,8balpha)]-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione |
| mitomycin C | s8146 |
1. Chan et al. (2005)